Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study
Aisling R. Caffrey, Haley J. Appaneal, Kerry L. LaPlante, Vrishali V. Lopes, Erlinda R. Ulloa, Victor Nizet, George Sakoulas
Abstract
= 147 propensity score-matched pairs): the inpatient mortality hazard ratio (HR) was 0.11 (95% confidence interval [CI], 0.01 to 0.86), and 30-day mortality HR was 0.43 (95% CI, 0.19 to 0.98). There were no differences in 30-day readmission, 30-day S. aureus reinfection, microbiological clearance, or thrombocytopenia. Clopidogrel use at the time of infection reduced in-hospital mortality by 89% and 30-day mortality by 57% among a cohort of patients with S. aureus bacteremia. These results support the need to further study the use of P2Y12 inhibitors as adjunctive therapy in S. aureus bloodstream infections.
Topics & Concepts
MedicineBacteremiaRetrospective cohort studyInternal medicinePropensity score matchingClopidogrelHazard ratioP2Y12Staphylococcus aureusProportional hazards modelCohortConfidence intervalAntibioticsAspirinMicrobiologyBacteriaGeneticsBiologyCentral Venous Catheters and HemodialysisHeparin-Induced Thrombocytopenia and ThrombosisAntiplatelet Therapy and Cardiovascular Diseases